| Code | CSB-RA022590MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Leukotuximab, designed to specifically target SPN (Sialophorin), also known as CD43 or leukosialin. SPN is a heavily glycosylated transmembrane protein predominantly expressed on the surface of hematopoietic cells, including T lymphocytes, monocytes, granulocytes, and certain B cell subsets. This sialomucin plays critical roles in cell adhesion, T cell activation, and immune cell trafficking through its anti-adhesive properties and signaling functions. Aberrant SPN expression has been implicated in various hematological malignancies, particularly acute lymphoblastic leukemia and non-Hodgkin lymphomas, as well as in inflammatory and autoimmune disorders where altered immune cell migration contributes to pathogenesis.
Leukotuximab, the reference antibody, has been utilized in immunological research to investigate lymphocyte biology, immune cell differentiation, and hematological disease mechanisms. This biosimilar provides researchers with a reliable tool for studying SPN-mediated cellular processes, examining immune cell phenotyping, and exploring therapeutic strategies targeting hematopoietic malignancies and immune-related conditions.
There are currently no reviews for this product.